Sandoz AG

Industry

  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
    • Vaccines

Other Names/Subsidiaries

  • Sandoz International GmbH
  • 1 A Pharma
  • Hexal
  • Lek
See more in Biomedtracker

Latest on Sandoz AG

Generics Bulletin

Rage Against The Machine: Generics CEOs Slam Systemic Problems In The US

 
• By Dave Wallace

“The more time I spend here, the more confused I become.” That was the verdict of Sandoz CEO Richard Saynor on the various frustrations of the US off-patent market, as he explored dysfunctional elemen

Generics Bulletin

Who’s Hired? Botox Biosimilar Developer Aeon Takes CEO From Rival Revance

 
• By Dave Wallace

Aeon Biopharma, which is working on developing a biosimilar version of Botox (onabotulinumtoxinA) in the US, has looked to rival developer Revance Therapeutics to recruit its new chief executive. Aeon

Generics Bulletin

Sandoz Admits To Widescale Infringement In Resolving US Rinvoq Patent Tussle

 
• By Dean Rudge

Sandoz has resolved its Hatch-Waxman patent-infringement dispute with AbbVie in the US over the originator’s Rinvoq (upadacitinib) extended-release tablets, declaring that its proposed abbreviated new

Generics Bulletin

Sandoz Attacks Amgen Over US Enbrel Exclusivity

 
• By Dave Wallace

After Sandoz several years ago lost US patent litigation with Amgen over Enbrel (etanercept) – preventing Sandoz from launching its Erelzi (etanercept-szzs) version until 2029 – the firm is now tryi